Publicaties

Jongen PJ. Cerebrovascular accident and sinus thrombosis in a patient treated with B-interferon. Letter (WriteClick®). Neurology, 26 June 2017. Full text

Jongen PJ. Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. Review Article. CNS Drugs 2017. doi:10.1007/s40263-017-0444-x. Full text

Jongen PJ, Lemmens WA, Hoogervorst EL, Donders R. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study). Health Qual Life Outcomes. 2017 Mar 14;15(1):50. doi: 10.1186/s12955-017-0622-z. Full text

Van der Hiele K, van Gorp DAM, Benedict RHB, Jongen PJ, Arnoldus EPJ, Beenakker EAC,Bos HM, van Eijk JJJ, Fermont J, Frequin STFM, van Geel BM, Hengstman  GJD, Hoitsma E, Hupperts RM, Mostert JP, Pop PHM, Verhagen WIM, Zemel D, Frndak SE, Heerings MAP, Middelkoop HAM, Visser LH. Coping strategies in relation to negative work events and accommodations in employed multiple sclerosis patients. Multiple Sclerosis Journal Experimental, Translational and Clinical, November 2016; vol. 2: 1-9, DOI: 10.1177/2055217316680638. Full text

Kremer IE, Evers SM, Jongen PJ, van der Weijden T, van de Kolk I, Hiligsmann M. Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling. PLoS One. 2016 Nov 3;11(11):e0164862. doi: 10.1371/journal.pone.0164862. Full text

Traboulsee AL, Cornelisse P, Sandberg-Wollheim M, Uitdehaag BMJ, Kappos L, Jongen PJ, Constantinescu CS, Verdun di Cantogno E, Li DKB. Prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical, January-December 2016; vol. 2, DOI: 2055217316666406, first published on September 6, 2016. Full text

Jongen PJ, Heerings M, Ruimschotel R, Hussaarts A, Duyverman L, van der Zande A, Valkenburg-Vissers J, van Droffelaar M, Lemmens W, Donders R, Visser LH. Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later. BMC Res Notes. 2016 Jul 29;9:375. doi: 10.1186/s13104-016-2173-5. Full text

Jongen S, Verhagen W, Verheul F, Sinnige O. MSmonitor blijkt zinvolle e-healthtoepassing MEDISCH CONTACT. Nr. 29/30 - 21 juli 2016:36-39. Full text

Jongen PJ, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen WH, Sinnige LG, Verhagen WI, Visser LH, van der Kruijk R, Verheul F, Boringa J, Heerings M, Gladdines W, Lönnqvist F, Gaillard P. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. J Neurol. 2016 Aug;263(8):1641-51. doi: 10.1007/s00415-016-8183-3. Epub 2016 Jun 7. Full text

Jongen PJ, Heerings M, Ruimschotel R, Hussaarts A, Evers S, Duyverman L, Valkenburg-Vissers J, Cornelissen J, Bos M, van Droffelaar M, Lemmens WA, Donders R, van der Zande A, Visser LH. An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol. BMC Neurol. 2016 May 28;16:81. doi: 10.1186/s12883-016-0593-4. Full text

Jongen PJ, Lemmens WA, Hupperts R, Hoogervorst E, Schrijver HM, Slettenaar A, de Schryver EL, Boringa J, van Noort E, Donders R. Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Prefer Adherence. 2016 May 24;10:909-17. doi: 10.2147/PPA.S108121. eCollection 2016. Full text

Visser LH, Heerings MA, Jongen PJ, van der Hiele K. Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment. Patient Prefer Adherence. 2016 Apr 26;10:659-67. doi: 10.2147/PPA.S106155. eCollection 2016. Full text

Jongen PJ, Sinnige LG, van Geel BM, Verheul F, Verhagen WI, van der Kruijk RA, Haverkamp R, Schrijver HM, Baart JC, Visser LH, Arnoldus EP, Gilhuis HJ, Pop P, Booy M, Heerings M, Kool A, van Noort E. The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: utilization and valuation by patients. Patient Prefer Adherence. 2016 Mar 3;10:243-50. doi: 10.2147/PPA.S93786. eCollection 2016. Full text

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas; Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Full text

Jongen PJ, Sinnige LG, van Geel BM, Verheul F, Verhagen WI, van der Kruijk RA, Haverkamp R, Schrijver HM, Baart JC, Visser LH, Arnoldus EP, Gilhuis HJ, Pop P, Booy M, Lemmens W, Donders R, Kool A, van Noort E. The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results. Patient Prefer Adherence. 2015 Dec 11;9:1741-50. doi: 10.2147/PPA.S93783. eCollection 2015. Full text

Kremer IE, Evers SM, Jongen PJ, Dowie J, van der Weijden T, van de Kolk I, Hiligsmann M. Preferences of Patients With Multiple Sclerosis for Attributes of Disease Modifying Drugs In Decision-Making: A Nominal Group Technique And Best-Worst Scaling. Value Health. 2015 Nov;18(7): A761. doi: 10.1016/j.jval.2015.09.2487. Epub 2015 Oct 20. 

Jongen PJ, Blok BF, Heesakkers JP, Heerings M, Lemmens WA, Donders R. Validation of a Dutch version of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: an observational web-based study. Health Qual Life Outcomes. 2015 Oct 30;13(1):175. doi: 10.1186/s12955-015-0368-4. Full text

Jongen PJ, Blok BF, Heesakkers JP, Heerings M, Lemmens WA, Donders R. Simplified scoring of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: a comparative analysis of test performance at different cut-off points. BMC Urol. 2015 Oct 24;15(1):106. doi: 10.1186/s12894-015-0100-z. Full text

van der Hiele K, van Gorp DA, Heerings MA, van Lieshout I, Jongen PJ, Reneman MF, van der Klink JJ, Vosman F, Middelkoop HA, Visser LH; MS@Work Study Group. The MS@Work study: a 3-year prospective observational study on factors involved with work participation in patients with relapsing-remitting Multiple Sclerosis. BMC Neurol. 2015 Aug 12;15:134. doi: 10.1186/s12883-015-0375-4.

Jongen PJ, Heerings M, Lemmens WA, Donders R, van der Zande A, van Noort E, Kool A. A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol. BMC Neurol. 2015 Aug 4;15:128. doi: 10.1186/s12883-015-0379-0.

Jongen PJ, Wesnes K, van Geel B, Pop P, Schrijver H, Visser LH, Gilhuis HJ, Sinnige JG, Brands AM. Does Self-Efficacy Affect Cognitive Performance in Persons with Clinically Isolated Syndrome and Early Relapsing Remitting Multiple Sclerosis? Multiple Sclerosis International 2015, Article ID 960282, 8 pages Full text

de Bock L, Somers K, Fraussen J, Hendriks JJ, van Horssen J, Rouwette M, Hellings N, Villar LM, Alvarez-Cermeño JC, Espiño M, Hupperts R, Jongen P, Damoiseaux J, Verbeek MM, De Deyn PP, D'hooghe M, Van Wijmeersch B, Stinissen P, Somers V. Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosis. J Immunol. 2014 Sep 1;193(5):2147-56. doi: 10.4049/jimmunol.1401166. Epub 2014 Aug 1. PubMed Abstract

Jongen PJ, Lehnick D, Koeman J, Frequin S, Heersema D, Kornips B, Schyns-Soeterboek A, Visser LH, Schiphof P, Valkenburg A, Hiel J; FOCUS Extension Study Group. Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study. J Neurol. 2014 Aug;261(8):1469-76. doi: 10.1007/s00415-014-7363-2. Epub 2014 May 3. Full Text

Jongen PJ, Wesnes K, van Geel B, Pop P, Sanders E, Schrijver H, Visser LH, Gilhuis HJ, Sinnige LG, Brands AM; COGNISEC Study Group. Relationship between working hours and power of attention, memory, fatigue, depression and self-efficacy one year after diagnosis of clinically isolated syndrome and relapsing remitting multiple sclerosis. PLoS One. 2014 May 1;9(5):e96444. doi: 10.1371/journal.pone.0096444. eCollection 2014. Full Text

Jongen PJ, Ruimschotel R, Heerings M, Hussaarts A, Duyverman L, van der Zande A, Valkenburg-Vissers J, Wolper H, van Droffelaar M, Lemmens W, Donders R, Visser LH. Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study. Health Qual Life Outcomes. 2014 Mar 19;12:40. doi: 10.1186/1477-7525-12-40. Full Text

Rouwette M, Noben JP, Van Horssen J, Van Wijmeersch B, Hupperts R, Jongen PJ, Verbeek MM, De Deyn PP, Stinissen P, Somers V. Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis.J Neurochem. 2013 Aug;126(4):483-92. doi: 10.1111/jnc.12335. Epub 2013 Jul 1. Full Text

Jongen PJ, Sanders E†, Zwanikken C, Koeman J, Visser LH, Koopmans P, Lehnick D, OPTIVIT study group. Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment. Patient Prefer Adherence. 2013 Apr 9;7:293-300. doi: 10.2147/PPA.S40173. Print 2013. PubMed Abstract

Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler. 2013 Sep;19(10):1310-9. doi: 10.1177/1352458513475723. Epub 2013 Feb 27. PubMed Abstract

Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol. 2012 Oct;69(10):1259-69. PubMed Abstract

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012 May;11(5):420-8. Epub 2012 Apr 10. PubMed Abstract

Jongen PJ, Ter Horst AT, Brands AM. Cognitive impairment in multiple sclerosis. Minerva Med 2012 Apr;103(2):73-96. PubMed Abstract

Jongen PJ. E-Health 2.0 Developments in Treatment and Research in Multiple Sclerosis. In:  Immunosuppression - Role in Health and Diseases, onder redactie van S. Kapur en M. Barbosa Portela, pp 457-470. InTech www.intechopen.com . ISBN 978-953-51-0152-9. Full Text

Jongen PJ, Sindic C, Sanders E, Hawkins S, Linssen W, van Munster E, Frequin S, Borm G; and the Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients (FLAIR) Study Group. Adverse Events of Interferon Beta-1a: A Prospective Multi-Centre International ICH-GCP-Based CRO-Supported External Validation Study in Daily Practice. PLoS One. 2011;6(10):e26568. Epub 2011 Oct 25. Full Text

O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293-303. PubMed Abstract

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5. PubMed Abstract

Edgar C, Jongen PJ, Sanders E, Sindic C, Goffette S, Dupuis M, Jacquerye P, Guillaume D, Reznik R, Wesnes K. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. BMC Neurol. 2011 Jun 7;11:68. Full Text

Jongen PJ, Hengstman G, Hupperts R, Schrijver H, Gilhuis J, Vliegen JH, Hoogervorst E, van Huizen M, van Munster E, Samijn J, de Schryver E, Siepman T, Tonk M, Zandbergen E, ten Holter J, van der Kruijk R, Borm G. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study). BMC Neurol. 2011 Mar 30;11:40. Full Text

Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011 Jan;69(1):75-82. doi: 10.1002/ana.22316. PubMed Abstract

Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M, Speck J; FOCUS study Group. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes. 2010 Nov 15;8:133. Full Text

Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC; GAP Study Group. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011 Jan;18(1):69-77. doi: 10.1111/j.1468-1331.2010.03110.x. PubMed Abstract

Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 Jul;9(7):672-80. Epub 2010 Jun 9. PubMed Abstract

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A,Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci. 2010 May 15;292(1-2):28-35. Epub 2010 Mar 16. PubMed Abstract

Verbeek MM, Lefeber DJ, Jongen PJ. Chitotriosidase activity in controls and multiple sclerosis. Acta Neurol Scand. 2010 May;121(5):356-7. doi: 10.1111/j.1600-0404.2010.01339.x. Epub 2010 Mar 1. Comment on Peripheral chitotriosidase in patients with multiple sclerosis [Acta Neurol Scand. 2010] and Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis [Acta Neurol Scand. 2010] Geen PubMed Abstract beschikbaar

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387-401. Epub 2010 Jan 20. PubMed Abstract

Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G; Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients study group. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. J Neurol. 2010 Apr;257(4):584-9. doi: 10.1007/s00415-009-5378-x. Epub 2009 Nov 18. PubMed Abstract

Tjon Eng Soe SH, Kopsky DJ, Jongen PJ, de Vet HC, Oei-Tan CL. Multiple sclerosis patients with bladder dysfunction have decreased symptoms after electro-acupuncture. Mult Scler. 2009 Nov;15(11):1376-7. Geen PubMed Abstract beschikbaar.

Verbeek MM, Notting EA, Faas B, Claessens-Linskens R, Jongen PJ. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis. Acta Neurol Scand. 2010 May;121(5):309-14. Epub 2009 Nov 19. PubMed Abstract

Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G; Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients study group. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. J Neurol. 2010 Apr;257(4):584-9. Epub 2009 Nov 18. PubMed Abstract

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. PubMed Abstract

Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol Dl, van Walderveen MA, Polman CH, Castelijns JA, Barkhof F. Association between MRI parameters and the MS severity scale: a 12 year follow-up study. Mult Scler. 2009 May;15(5):632-7. doi: 10.1177/1352458509102617. PubMed Abstract

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11. PubMed Abstract